PHASE-I TRIAL OF N-(PHOSPHONACETYL)-L-ASPARTATE
- 1 January 1979
- journal article
- research article
- Vol. 39 (10) , 3992-3995
Abstract
A Phase I clinical trial of N-(phosphonacetyl)-L-aspartate, an antimetabolite which inhibits a key enzyme in the de novo pathway of pyrimidine biosynthesis, was conducted. N-(Phosphonacetyl)-L-aspartate was given as an i.v. 15 min infusion once daily for 5 days; cycles of treatment were repeated every 3 wk. Patients (34) received treatment. Dose-limiting toxicity was observed at 1500-2000 mg/m2 per day and was manifested by sin rash, diarrhea and stomatitis. Rash and diarrhea usually began during the 1st wk of treatment and persisted up to day 17 of a cycle of therapy. No consistent hematopoietic, heptic or renal toxicity was observed. One partial response in a patient with colon carcinoma was seen and continues at more than 8 mo. Stable disease was observed in 3 patients with colon carcinoma, 2 patients with hypernephroma, 1 patient with pancreatic carcinoma, and one patient with melanoma. The predictability and reversibility of toxicity and the suggestion of antitumor activity in humans support the further evaluation of N-(phosphonacetyl)-L-aspartate in Phase II studies.This publication has 5 references indexed in Scilit:
- DETERMINATION OF N-(PHOSPHONACETYL)-L-ASPARTIC ACID (PALA) IN DOG SERUM AND URINE BY GAS-CHROMATOGRAPHY AND SELECTED ION MONITORING1979
- EFFECTS OF N-(PHOSPHONACETYL)-L-ASPARTATE ON MURINE TUMORS AND NORMAL TISSUES INVIVO AND INVITRO AND RELATIONSHIP OF SENSITIVITY TO RATE OF PROLIFERATION AND LEVEL OF ASPARTATE-TRANSCARBAMYLASE1978
- Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-aspartate in vivoBiochemical Pharmacology, 1977
- Stable mutants of mammalian cells that overproduce the first three enzymes of pyrimidine nucleotide biosynthesisCell, 1976
- ANTITUMOR ACTIVITY OF N-(PHOSPHONACETYL)-L-ASPARTIC ACID, A TRANSITION-STATE INHIBITOR OF ASPARTATE-TRANSCARBAMYLASE1976